{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(6)"],"submitter":["Uehara Y"],"pubmed_abstract":["<h4>Background</h4>We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers.<h4>Materials and methods</h4>We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes [University of California San Diego Molecular Tumor Board (MTB) (N = 16)].<h4>Results</h4>Patients whose cancers harbored FGF/FGFR alterations (N = 1074) versus those without them (N = 6500) had shorter overall survival (OS) (median: 23.1 versus 26.4 months, P = 0.038) (cBioPortal). Only 6.1% (65/1074 patients) had no pathogenic co-alterations accompanying FGF/FGFR axis abnormalities. The most frequently co-altered pathways/genes involved: TP53 (70%); cell cycle (58%); PI3K (55%); a"],"journal":["ESMO open"],"pagination":["100647"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9808461"],"repository":["biostudies-literature"],"pubmed_title":["Targeting the FGF/FGFR axis and its co-alteration allies."],"pmcid":["PMC9808461"],"pubmed_authors":["Okamura R","Lee S","Sicklick JK","Kurzrock R","Ikeda S","Lim HJ","Kim KH","Uehara Y","Kato S","Persha HE","Adashek JJ"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the FGF/FGFR axis and its co-alteration allies.","description":"<h4>Background</h4>We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers.<h4>Materials and methods</h4>We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes [University of California San Diego Molecular Tumor Board (MTB) (N = 16)].<h4>Results</h4>Patients whose cancers harbored FGF/FGFR alterations (N = 1074) versus those without them (N = 6500) had shorter overall survival (OS) (median: 23.1 versus 26.4 months, P = 0.038) (cBioPortal). Only 6.1% (65/1074 patients) had no pathogenic co-alterations accompanying FGF/FGFR axis abnormalities. The most frequently co-altered pathways/genes involved: TP53 (70%); cell cycle (58%); PI3K (55%); a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-03-16T08:10:30.452Z","creation":"2025-04-19T04:47:45.493Z"},"accession":"S-EPMC9808461","cross_references":{"pubmed":["36455506"],"doi":["10.1016/j.esmoop.2022.100647"]}}